Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice

C. Casnici, G. Volpe, D. Lattuada, K. Crotta, M. Kuka, C. Panuzzo, C. Mastrotto, G. Tonon, V. M. Fazio, G. Saglio, O. Marelli

Research output: Contribution to journalArticle

Abstract

New, potentially tumor-specific antigens have been described in Bcr/Abl positive leukemias. Besides the main BCR/ABL hybrid fusion transcripts, a small number of transcripts derived from alternative splicing between BCR exons 1, 13, and 14 with ABL exons 4 and 5 have been identified. These variants are expressed in chronic myelogenous leukemia and acute lymphocytic leukemia patients. The transcriptional products were characterized at their C-terminus by a large amino acid portion derived from out of frame (OOF) reading of the ABL gene. This OOF peptide is expressed only in leukemic cells and has no homology with known human proteins. In order to study an in vivo model, three 39-amino acid peptides, each corresponding to a third of the whole human OOF peptide sequence, were tested for their capacity to elicit specific immune responses in HLA A2.1 transgenic mice. Peptides A and B, but not C, induced the production of specific antisera, while A and C induced the generation of specific cytotoxic T lymphocytes.

Original languageEnglish
Pages (from-to)61-67
Number of pages7
JournalCancer Letters
Volume276
Issue number1
DOIs
Publication statusPublished - Apr 8 2009

Fingerprint

Alternative Splicing
Transgenic Mice
Peptides
Exons
Amino Acids
Reading Frames
Cytotoxic T-Lymphocytes
Neoplasm Antigens
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immune Sera
Leukemia
Genes
Proteins

Keywords

  • BCR/ABL transcripts
  • Cancer vaccine
  • Chronic myelogenous leukemia
  • HLA A2.1 transgenic mice
  • Peptide vaccination

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Casnici, C., Volpe, G., Lattuada, D., Crotta, K., Kuka, M., Panuzzo, C., ... Marelli, O. (2009). Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice. Cancer Letters, 276(1), 61-67. https://doi.org/10.1016/j.canlet.2008.10.032

Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice. / Casnici, C.; Volpe, G.; Lattuada, D.; Crotta, K.; Kuka, M.; Panuzzo, C.; Mastrotto, C.; Tonon, G.; Fazio, V. M.; Saglio, G.; Marelli, O.

In: Cancer Letters, Vol. 276, No. 1, 08.04.2009, p. 61-67.

Research output: Contribution to journalArticle

Casnici, C, Volpe, G, Lattuada, D, Crotta, K, Kuka, M, Panuzzo, C, Mastrotto, C, Tonon, G, Fazio, VM, Saglio, G & Marelli, O 2009, 'Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice', Cancer Letters, vol. 276, no. 1, pp. 61-67. https://doi.org/10.1016/j.canlet.2008.10.032
Casnici, C. ; Volpe, G. ; Lattuada, D. ; Crotta, K. ; Kuka, M. ; Panuzzo, C. ; Mastrotto, C. ; Tonon, G. ; Fazio, V. M. ; Saglio, G. ; Marelli, O. / Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice. In: Cancer Letters. 2009 ; Vol. 276, No. 1. pp. 61-67.
@article{b15e553c44e3499cbd837572e3caa94a,
title = "Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice",
abstract = "New, potentially tumor-specific antigens have been described in Bcr/Abl positive leukemias. Besides the main BCR/ABL hybrid fusion transcripts, a small number of transcripts derived from alternative splicing between BCR exons 1, 13, and 14 with ABL exons 4 and 5 have been identified. These variants are expressed in chronic myelogenous leukemia and acute lymphocytic leukemia patients. The transcriptional products were characterized at their C-terminus by a large amino acid portion derived from out of frame (OOF) reading of the ABL gene. This OOF peptide is expressed only in leukemic cells and has no homology with known human proteins. In order to study an in vivo model, three 39-amino acid peptides, each corresponding to a third of the whole human OOF peptide sequence, were tested for their capacity to elicit specific immune responses in HLA A2.1 transgenic mice. Peptides A and B, but not C, induced the production of specific antisera, while A and C induced the generation of specific cytotoxic T lymphocytes.",
keywords = "BCR/ABL transcripts, Cancer vaccine, Chronic myelogenous leukemia, HLA A2.1 transgenic mice, Peptide vaccination",
author = "C. Casnici and G. Volpe and D. Lattuada and K. Crotta and M. Kuka and C. Panuzzo and C. Mastrotto and G. Tonon and Fazio, {V. M.} and G. Saglio and O. Marelli",
year = "2009",
month = "4",
day = "8",
doi = "10.1016/j.canlet.2008.10.032",
language = "English",
volume = "276",
pages = "61--67",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice

AU - Casnici, C.

AU - Volpe, G.

AU - Lattuada, D.

AU - Crotta, K.

AU - Kuka, M.

AU - Panuzzo, C.

AU - Mastrotto, C.

AU - Tonon, G.

AU - Fazio, V. M.

AU - Saglio, G.

AU - Marelli, O.

PY - 2009/4/8

Y1 - 2009/4/8

N2 - New, potentially tumor-specific antigens have been described in Bcr/Abl positive leukemias. Besides the main BCR/ABL hybrid fusion transcripts, a small number of transcripts derived from alternative splicing between BCR exons 1, 13, and 14 with ABL exons 4 and 5 have been identified. These variants are expressed in chronic myelogenous leukemia and acute lymphocytic leukemia patients. The transcriptional products were characterized at their C-terminus by a large amino acid portion derived from out of frame (OOF) reading of the ABL gene. This OOF peptide is expressed only in leukemic cells and has no homology with known human proteins. In order to study an in vivo model, three 39-amino acid peptides, each corresponding to a third of the whole human OOF peptide sequence, were tested for their capacity to elicit specific immune responses in HLA A2.1 transgenic mice. Peptides A and B, but not C, induced the production of specific antisera, while A and C induced the generation of specific cytotoxic T lymphocytes.

AB - New, potentially tumor-specific antigens have been described in Bcr/Abl positive leukemias. Besides the main BCR/ABL hybrid fusion transcripts, a small number of transcripts derived from alternative splicing between BCR exons 1, 13, and 14 with ABL exons 4 and 5 have been identified. These variants are expressed in chronic myelogenous leukemia and acute lymphocytic leukemia patients. The transcriptional products were characterized at their C-terminus by a large amino acid portion derived from out of frame (OOF) reading of the ABL gene. This OOF peptide is expressed only in leukemic cells and has no homology with known human proteins. In order to study an in vivo model, three 39-amino acid peptides, each corresponding to a third of the whole human OOF peptide sequence, were tested for their capacity to elicit specific immune responses in HLA A2.1 transgenic mice. Peptides A and B, but not C, induced the production of specific antisera, while A and C induced the generation of specific cytotoxic T lymphocytes.

KW - BCR/ABL transcripts

KW - Cancer vaccine

KW - Chronic myelogenous leukemia

KW - HLA A2.1 transgenic mice

KW - Peptide vaccination

UR - http://www.scopus.com/inward/record.url?scp=60549094771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60549094771&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2008.10.032

DO - 10.1016/j.canlet.2008.10.032

M3 - Article

C2 - 19062160

AN - SCOPUS:60549094771

VL - 276

SP - 61

EP - 67

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -